Across TCGA pan-cancer cohorts, ENTPD7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENTPD7 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ENTPD7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENTPD7 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where ENTPD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.265	0.459	.034	23	view →
LUAD	OS	Tertile	II,III,IV	0.255	0.790	.007	16	view →
HNSC	DFS	Quartile	All	0.917	0.623	.006	13	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ENTPD7 tumor-vs-normal RNA expression · all ENTPD7 data types